Compressed SPEEDER Technology for 3D Exams On 1.5T MR, Enabling High-speed MR Imaging Now FDA Approved

December 21, 2020

Compressed SPEEDER technology for 3D exams has been FDA-cleared for 3D sequences on Canon Medical Systems USA, Inc.’s Vantage Orian 1.5T MR system, so clinicians can easily expect to scan at least twice as fast, and even faster in many clinical scenarios*.

Compressed SPEEDER 3D** boosts MRI scan times during 3D sequences for exams such as surgical planning and orthopedic applications by reconstructing full resolution images from under-sampled data through iterative reconstruction. The innovative technique overcomes many of the limitations inherent to traditional parallel imaging and allows for greater acceleration. The system can even further accelerate exams with Fast3D, a new technique that can be used in combination with Compressed SPEEDER 3D to help make exams even quicker.

Compressed SPEEDER technology is available as an option in an all-new new version of M-Power software for the Vantage Orian 1.5T, which is also available with Fat Fraction Quantification**, an application integrated directly onto the system’s console to help clinicians image and quantify fatty liver disease. The application acquires six MR echoes at once, allowing for quick diagnoses, detailed severity grading, disease monitoring and treatment response, all in alignment with QIBA standards.

“With 30 percent of the U.S. population suffering from Fatty Liver Disease, the ability to diagnose quickly as well as quantify and monitor the disease has become extremely important to clinicians. Our Fat Fraction Quantification is an ideal solution, and it is on our Vantage Orian 1.5T console so that it can be integrated into existing workflow,” said Jonathan Furuyama, managing director, MR Business Unit, Canon Medical Systems USA, Inc.

Furuyama concluded, “At Canon Medical, our priority is to support our customers and their patients by providing them with timely advancements that can impact their outcomes and workflow. With the help of Compressed SPEEDER for 3D exams along with Fat Fraction Quantification, healthcare providers can offer a quick and comfortable experience for their patients.”


* Actual acceleration factors vary by case. Maximum acceleration factor is up to 16 times.

** Compressed SPEEDER 3D and Fat Fraction Quantification are both optional. Fat Fraction Quantification is FI-Quant.

Vantage Orian and Made for life are trademarks of Canon Medical Systems.

SourceCanon

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”